Virologic Monitoring of Hepatitis B Virus Therapy in Clinical Trials and Practice: Recommendations for a Standardized Approach

Jean Michel Pawlotsky, Geoffrey Dusheiko, Angelos Hatzakis, Daryl Lau, George Lau, T. Jake Liang, Stephen Locarnini, Paul Martin, Douglas D. Richman, Fabien Zoulim

Research output: Contribution to journalArticle

190 Citations (Scopus)

Abstract

Treatment of chronic hepatitis B virus (HBV) infection is aimed at suppressing viral replication to the lowest possible level, and thereby to halt the progression of liver disease and prevent the onset of complications. Two categories of drugs are used in HBV therapy: the interferons, including standard interferon alfa or pegylated interferon alfa, and specific nucleoside or nucleotide HBV inhibitors that target the reverse-transcriptase function of HBV-DNA polymerase. The reported results of clinical trials have used varying definitions of efficacy, failure, and resistance based on different measures of virologic responses. This article discusses HBV virologic markers and tests, and their optimal use both for planning and reporting clinical trials and in clinical practice.

Original languageEnglish
Pages (from-to)405-415
Number of pages11
JournalGastroenterology
Volume134
Issue number2
DOIs
StatePublished - Feb 1 2008
Externally publishedYes

Fingerprint

Hepatitis B virus
Clinical Trials
Interferon-alpha
Therapeutics
Reverse Transcriptase Inhibitors
Chronic Hepatitis B
Virus Diseases
DNA-Directed DNA Polymerase
Nucleosides
Interferons
Liver Diseases
Nucleotides
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Virologic Monitoring of Hepatitis B Virus Therapy in Clinical Trials and Practice : Recommendations for a Standardized Approach. / Pawlotsky, Jean Michel; Dusheiko, Geoffrey; Hatzakis, Angelos; Lau, Daryl; Lau, George; Liang, T. Jake; Locarnini, Stephen; Martin, Paul; Richman, Douglas D.; Zoulim, Fabien.

In: Gastroenterology, Vol. 134, No. 2, 01.02.2008, p. 405-415.

Research output: Contribution to journalArticle

Pawlotsky, JM, Dusheiko, G, Hatzakis, A, Lau, D, Lau, G, Liang, TJ, Locarnini, S, Martin, P, Richman, DD & Zoulim, F 2008, 'Virologic Monitoring of Hepatitis B Virus Therapy in Clinical Trials and Practice: Recommendations for a Standardized Approach', Gastroenterology, vol. 134, no. 2, pp. 405-415. https://doi.org/10.1053/j.gastro.2007.11.036
Pawlotsky, Jean Michel ; Dusheiko, Geoffrey ; Hatzakis, Angelos ; Lau, Daryl ; Lau, George ; Liang, T. Jake ; Locarnini, Stephen ; Martin, Paul ; Richman, Douglas D. ; Zoulim, Fabien. / Virologic Monitoring of Hepatitis B Virus Therapy in Clinical Trials and Practice : Recommendations for a Standardized Approach. In: Gastroenterology. 2008 ; Vol. 134, No. 2. pp. 405-415.
@article{3051ecdbf9cb447f8b49026f22ea4011,
title = "Virologic Monitoring of Hepatitis B Virus Therapy in Clinical Trials and Practice: Recommendations for a Standardized Approach",
abstract = "Treatment of chronic hepatitis B virus (HBV) infection is aimed at suppressing viral replication to the lowest possible level, and thereby to halt the progression of liver disease and prevent the onset of complications. Two categories of drugs are used in HBV therapy: the interferons, including standard interferon alfa or pegylated interferon alfa, and specific nucleoside or nucleotide HBV inhibitors that target the reverse-transcriptase function of HBV-DNA polymerase. The reported results of clinical trials have used varying definitions of efficacy, failure, and resistance based on different measures of virologic responses. This article discusses HBV virologic markers and tests, and their optimal use both for planning and reporting clinical trials and in clinical practice.",
author = "Pawlotsky, {Jean Michel} and Geoffrey Dusheiko and Angelos Hatzakis and Daryl Lau and George Lau and Liang, {T. Jake} and Stephen Locarnini and Paul Martin and Richman, {Douglas D.} and Fabien Zoulim",
year = "2008",
month = "2",
day = "1",
doi = "10.1053/j.gastro.2007.11.036",
language = "English",
volume = "134",
pages = "405--415",
journal = "Gastroenterology",
issn = "0016-5085",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - Virologic Monitoring of Hepatitis B Virus Therapy in Clinical Trials and Practice

T2 - Recommendations for a Standardized Approach

AU - Pawlotsky, Jean Michel

AU - Dusheiko, Geoffrey

AU - Hatzakis, Angelos

AU - Lau, Daryl

AU - Lau, George

AU - Liang, T. Jake

AU - Locarnini, Stephen

AU - Martin, Paul

AU - Richman, Douglas D.

AU - Zoulim, Fabien

PY - 2008/2/1

Y1 - 2008/2/1

N2 - Treatment of chronic hepatitis B virus (HBV) infection is aimed at suppressing viral replication to the lowest possible level, and thereby to halt the progression of liver disease and prevent the onset of complications. Two categories of drugs are used in HBV therapy: the interferons, including standard interferon alfa or pegylated interferon alfa, and specific nucleoside or nucleotide HBV inhibitors that target the reverse-transcriptase function of HBV-DNA polymerase. The reported results of clinical trials have used varying definitions of efficacy, failure, and resistance based on different measures of virologic responses. This article discusses HBV virologic markers and tests, and their optimal use both for planning and reporting clinical trials and in clinical practice.

AB - Treatment of chronic hepatitis B virus (HBV) infection is aimed at suppressing viral replication to the lowest possible level, and thereby to halt the progression of liver disease and prevent the onset of complications. Two categories of drugs are used in HBV therapy: the interferons, including standard interferon alfa or pegylated interferon alfa, and specific nucleoside or nucleotide HBV inhibitors that target the reverse-transcriptase function of HBV-DNA polymerase. The reported results of clinical trials have used varying definitions of efficacy, failure, and resistance based on different measures of virologic responses. This article discusses HBV virologic markers and tests, and their optimal use both for planning and reporting clinical trials and in clinical practice.

UR - http://www.scopus.com/inward/record.url?scp=38749126832&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38749126832&partnerID=8YFLogxK

U2 - 10.1053/j.gastro.2007.11.036

DO - 10.1053/j.gastro.2007.11.036

M3 - Article

C2 - 18242209

AN - SCOPUS:38749126832

VL - 134

SP - 405

EP - 415

JO - Gastroenterology

JF - Gastroenterology

SN - 0016-5085

IS - 2

ER -